Wright Medical gets Japanese nod for hip resurfacing system:
This article was originally published in Clinica
Wright Medical has received regulatory approval from Japan's Ministry of Health, Labour and Welfare for its Conserve Plus hip resurfacing system. Hip resurfacing is a less invasive, bone sparing approach to hip surgery. The system is particularly aimed at younger, active patients suffering from chronic hip pain, and is designed to help patients achieve a greater range of motion and more natural gait, the Arlington, Tennessee company said. The Conserve plus system is currently available in Europe, Canada and Australia, among other markets. The product is yet to reach the US; Wright's premarket approval submission is still under FDA review.
You may also be interested in...
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
Market researcher The NPD Group identifies the few prestige beauty categories that posted sales growth in the US for the week ending 28 March. Companies that can pivot or ramp up activities in winning segments – and reach consumers digitally while they shelter at home – may fare best during the coronavirus pandemic.